Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,001–1,100 of 2,576
Ringman, J. M., Elashoff, D., Geschwind, D. H., Welsh, B. T., Gylys, K. H., Lee, C., Cummings, J. L., & Cole, G. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.277 · Cited by 56
α-synuclein induced synapse damage is enhanced by amyloid-β1-42
Bate, C., Gentleman, S., & Williams, A. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-55 · Cited by 59
“produced [24,25,51] and since Ab1-40 is the predominant Ab species formed in AD [29,52] the effect of Ab1-40 on aSN-induced loss of synaptophysin was also tested.”
MethodCalcium dyshomeostasis and neurotoxicity of Alzheimer’s β-amyloid protein
Kawahara, M., Kato‐Negishi, M., & Sadakane, Y. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.28 · Cited by 67
Castro, P., Zaman, S., & Holland, A. (2017) · Journal of Neurology · doi:10.1007/s00415-016-8308-8 · Cited by 55
Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology
Guo, J., Cheng, J., North, B. J., & Wei, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.07.001 · Cited by 55
Pérez‐González, R., Kim, Y., Miller, C., Pacheco‐Quinto, J., Eckman, E. A., & Levy, E. (2020) · The FASEB Journal · doi:10.1096/fj.202000823r · Cited by 52
Presenilin‐1 Exists in Both Pre‐ and Post‐Golgi Compartments and Recycles Via COPI‐Coated Membranes
Réchards, M., Xia, W., Oorschot, V. M. J., Selkoe, D. J., & Klumperman, J. (2003) · Traffic · doi:10.1034/j.1600-0854.2003.t01-1-00114.x · Cited by 55
Self-citationPresenilin mutations line up along transmembrane α-helices
Hardy, J., & Crook, R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01910-3 · Cited by 59
Self-citationDickerson, T. J., & Janda, K. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1332847100 · Cited by 58
Alzheimer's Disease-like Alterations in Peripheral Cells from Presenilin-1 Transgenic Mice
Eckert, A., Schindowski, K., Leutner, S., Luckhaus, C., Touchet, N., Czech, C., & Müller, W. E. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0378 · Cited by 61
“…which PS1 mutations lead to neurodegeneration in AD remains still to be identified, but seem to be associated with altered proteolytic processing of amyloid precursor protein (APP) and enhanced production of the amyloidogenic form of b-amyloid (Ab) 1–42 (Scheuner et al., 1996; Citron et al., 1997).”
The genetics of Alzheimer’s disease
Schellenberg, G. D., D’Souza, I., & Poorkaj, P. (2000) · Current Psychiatry Reports · doi:10.1007/s11920-000-0061-z · Cited by 56
Self-citationMolecular pathogenesis of sporadic and familial forms of Alzheimer's disease
Ray, W. J., Ashall, F., & Goate, A. (1998) · Molecular Medicine Today · doi:10.1016/s1357-4310(98)01229-5 · Cited by 61
Alzheimer Disease: Mouse Models Pave the Way for Therapeutic Opportunities
Emilien, G., Maloteaux, J.-M., Beyreuther, K., & Masters, C. L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.2.176 · Cited by 55
“Surprisingly, FAD-linked PS1/PS2 variants influence processing at the g-secretase site and may cause AD by increasing the extracellular concentration of highly amyloidogenic Ab42 species, thus fostering Ab deposition in the brain.(11) The age of onset of AD in families harboring PS1 mutations is young, ranging from 30…”
BackgroundIslam, F., Islam, M. R., Meem, A. F. K., Nafady, M. H., Islam, M. R., Akter, A., Mitra, S., Alhumaydhi, F. A., Emran, T. B., Khusro, A., et al. (2022) · Chemosphere · doi:10.1016/j.chemosphere.2022.136020 · Cited by 56
RetractedPathophysiological Links Among Hypertension and Alzheimer’s Disease
Carnevale, D., Perrotta, M., Lembo, G., & Trimarco, B. (2015) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-015-0108-1 · Cited by 61
Hwang, D. Y., Cho, J. S., Oh, J. H., Shim, S. B., Jee, S. W., Lee, S. H., Seo, S. J., Lee, S. K., Lee, S. H., & Kim, Y. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6787-6 · Cited by 63
“Missense mutations in PS genes result in an increasing of Ab-42 level in the plasma of AD patients that are caused by a shift of two amino acids in c-secretase’s preferred cleavage site on the APP sequence (11).”
BackgroundC1q binding and complement activation by prions and amyloids
Sim, R. B., Kishore, U., Villiers, C. L., Marche, P. N., & Mitchell, D. A. (2007) · Immunobiology · doi:10.1016/j.imbio.2007.04.001 · Cited by 54
Aguilar, M. I., & Small, D. H. (2005) · Neurotoxicity Research · doi:10.1007/bf03033773 · Cited by 62
Molecular Pathogenesis of Alzheimer’s Disease: Reductionist versus Expansionist Approaches
Castellani, R. J., Zhu, X., Lee, H.-G., Smith, M. A., & Perry, G. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10031386 · Cited by 54
“The presenilins, initially identified through linkage to early onset familial AD with apparent increased Aβ42 [11-13], are two candidates for the components of the γ-secretase complex [14].”
BackgroundJayne, T., Newman, M., Verdile, G., Sutherland, G. T., Münch, G. W., Musgrave, I., Nik, S. H. M., & Lardelli, M. T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151186 · Cited by 57
“, [9, 10]) and sAD [64] brains.”
BackgroundNeural stem/progenitor cells in Alzheimer's disease.
Tincer, G., Mashkaryan, V., Bhattarai, P., & Kızıl, Ç. (2016) · PubMed Central · Cited by 66
Mechanisms of neurodegeneration — Insights from familial Alzheimer’s disease
Chávez-Gutiérrez, L., & Szaruga, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.03.005 · Cited by 58
A novel presenilin mutation (M233V) causing very early onset Alzheimer's disease with Lewy bodies
Houlden, H., Crook, R., Dolan, R. J., McLaughlin, J., Révész, T., & Hardy, J. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02254-6 · Cited by 55
Self-citationHOCK, C., MADDALENA, A., HEUSER, I., NABER, D., OERTEL, W., VON DER KAMMER, H., WIENRICH, M., RASCHIG, A., DENG, M., GROWDON, J. H., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06937.x · Cited by 54
Askanas, V., Engel, W. K., Yang, C., Alvarez, R. B., Lee, V. M.-Y., & Wısnıewskı, T. (1998) · Europe PMC (PubMed Central) · Cited by 59
Aoki, M., Volkmann, I., Tjernberg, L. O., Winblad, B., & Bogdanovic, N. (2008) · NeuroReport · doi:10.1097/wnr.0b013e328302c858 · Cited by 53
5 Genetic Regulation of Somite Formation
Rawls, A., Wilson‐Rawls, J., & Olson, E. N. (1999) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(08)60724-3 · Cited by 59
Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Uddin, M. S., Hasana, S., Hossain, M. F., Islam, M. S., Behl, T., Perveen, A., Hafeez, A., & Ashraf, G. M. (2020) · Current Gene Therapy · doi:10.2174/1566523220666201123112822 · Cited by 64
pH Dependence of Amyloid‐β Fibril Assembly Kinetics: Unravelling the Microscopic Molecular Processes
Tian, Y., & Viles, J. H. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202210675 · Cited by 60
Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models
Maia, L. F., Kaeser, S. A., Reichwald, J., Lambert, M., Obermüller, U., Schelle, J., Odenthal, J., Martus, P., Staufenbiel, M., & Jucker, M. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505026 · Cited by 54
“However, DIAN includes subjects with different mutations (APP, presenilin 1, and presenilin 2) characterized by a heterogeneous over-production of Ab42, which may have masked any transient increase (Scheuner et al, 1996; Bateman et al, 2012; Potter et al, 2013).”
BackgroundPhysiological and pathological roles of the γ-secretase complex
Carroll, C. M., & Li, Y.-M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.04.019 · Cited by 53
Du, H., Liu, X., Xie, J., & Ma, F. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00699 · Cited by 55
Chami, M., & Checler, F. (2020) · Cells · doi:10.3390/cells9122577 · Cited by 56
Heritability of plasma amyloid β in typical late‐onset Alzheimer’s disease pedigrees
Ertekin‐Taner, N., Graff‐Radford, N., Younkin, L. H., Eckman, C., Adamson, J., Schaid, D. J., Blangero, J., Hutton, M., & Younkin, S. G. (2001) · Genetic Epidemiology · doi:10.1002/gepi.1015 · Cited by 54
“…in cells transfected with mutant PS1, PS2, and APP genes, transgenic mouse models of AD, and plasma and CSF from early onset AD cases and their first-degree relatives [Citron et al., 1992; Suzuki et al., 1994; Scheuner et al., 1996; Borchelt et al., 1996; Duff et al., 1996; Eckman et al., 1997].”
BackgroundSelf-citationMcFarlane, I., Georgopoulou, N., Coughlan, C. M., Gillian, A. M., & Breen, K. C. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00361-3 · Cited by 58
Mouse Models of Alzheimer's Disease: A Quest for Plaques
Richardson, J. A., & Burns, D. K. (2002) · ILAR Journal · doi:10.1093/ilar.43.2.89 · Cited by 53
Brain Aβ amyloidosis in APPsw mice induces accumulation of presenilin-1 and tau
Tomidokoro, Y., Harigaya, Y., Matsubara, E., Ikeda, M., Kawarabayashi, T., Shirao, T., Ishiguro, K., Okamoto, K., Younkin, S. G., & Shoji, M. (2001) · The Journal of Pathology · doi:10.1002/path.897 · Cited by 53
Self-citationAraki, W., Yuasa, K., Takeda, S., Takeda, K., Shirotani, K., Takahashi, K., & Tabira, T. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00638.x · Cited by 58
“…disease; MAP2, microtubule-associated protein 2; moi, multiplicity of infection; NTF, N-terminal fragments; PBS, phosphate-buffered saline; PS1 and PS2, presenilin 1 and 2; STS, staurosporine. of Ab42 production, the major type of Ab deposited in AD brain (Scheuner et al. 1996; Citron et al. 1997).”
BackgroundKawasumi, M., Hashimoto, Y., Chiba, T., Kanekura, K., Yamagishi, Y., Ishizaka, M., Tajima, H., Niikura, T., & Nishimoto, I. (2002) · Neurosignals · doi:10.1159/000067424 · Cited by 54
Therapeutic approaches to Alzheimer’s disease
Thorsett, E. D., & Latimer, L. H. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(00)00102-2 · Cited by 68
Enhanced generation of intracellular Aβ42 amyloid peptide by mutation of presenilins PS1 and PS2
Takeda, K., Araki, W., & Tabira, T. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2003.03135.x · Cited by 53
DNA methylation in neurodegenerative disorders: a missing link between genome and environment?
Iraola-Guzmán, S., Estivill, X., & Rabionet, R. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01673.x · Cited by 52
Bekris, L. M., Galloway, N. M., Millard, S., Lockhart, D., Li, G., Galasko, D. R., Farlow, M. R., Clark, C. M., Quinn, J. F., Kaye, J. A., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.020 · Cited by 54
“The majority of these mutations alter processing of APP so that the relative levels of Aβ42 are increased (Scheuner et al., 1996; Walker et al., 2005).”
Self-citationAquaporin-4 and Alzheimer’s Disease
Yang, C., Huang, X., Huang, X., Mai, H., Li, J., Jiang, T., Wang, X., & Lü, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150949 · Cited by 57
Zhou, R., Yang, G., & Shi, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713605114 · Cited by 53
Tauists and βaptists United--Well Almost!
Lee, V. M. ‐. (2001) · Science · doi:10.1126/science.1064684 · Cited by 56
Martin-Rehrmann, M. D., Hoe, H., Capuani, E. M., & Rebeck, G. W. (2005) · Neurotoxicity Research · doi:10.1007/bf03036452 · Cited by 55
“Genetic evidence supports neuropathological consequences for altered processing of the amyloid precursor protein (APP) in AD, and the resulting production of the 4 kDΑ β-amyloid (Aβ) peptide that is the primary component of senile plaques (Scheuner et al., 1996; Hardy, 1997; Selkoe, 1998).”
Cedazo-Mı́nguez, A., Popescu, B. O., Ankarcrona, M., Nishimura, T., & Cowburn, R. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112117200 · Cited by 51
van der Laan, L. J. W., Groot, C. J. A. D., Elices, M. J., & Dijkstra, C. D. (1997) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19971115)50:4<539::aid-jnr5>3.0.co;2-f · Cited by 38
Cerebrospinal fluid and blood biomarkers in Alzheimer’s disease
Humpel, C. (2011) · World Journal of Psychiatry · doi:10.5498/wjp.v1.i1.8 · Cited by 50
Amyloid β-induced erythrocytic damage and its attenuation by carotenoids
Nakagawa, K., Kiko, T., Miyazawa, T., Sookwong, P., Tsuduki, T., Satoh, A., & Miyazawa, T. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.060 · Cited by 57
Immune and myodegenerative pathomechanisms in inclusion body myositis
Keller, C. W., Schmidt, J., & Lünemann, J. D. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.419 · Cited by 66
Can zebrafish be used as animal model to study Alzheimer's disease?
Santana, S., Rico, E. P., & Burgos, J. S. (2012) · Europe PMC (PubMed Central) · Cited by 71
Paschen, W., & Mengesdorf, T. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.008 · Cited by 54
An Iranian family with Alzheimer’s disease caused by a novel APP mutation (Thr714Ala)
Pasalar, P., Najmabadi, H., Noorian, A. R., Moghimi, B., Jannati, A., Soltanzadeh, A., Krefft, T., Crook, R., & Hardy, J. (2002) · Neurology · doi:10.1212/wnl.58.10.1574 · Cited by 52
Self-citationAmyloid-beta and tau proteins as biochemical markers of Alzheimer's disease
Sobów, T., Flirski, M., & Liberski, P. P. (2004) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2004-1491 · Cited by 59
“Increased levels of A 42 are suggested to be an initiating factor for both sporadic and familial forms of AD (Scheuner et al. 1996).”
BackgroundHuman monoclonal antibodies against amyloid-beta from healthy adults
Geylis, V., Kourilov, V., Meiner, Z., Nennesmo, I., Bogdanović, N., & Steinitz, M. O. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.06.008 · Cited by 52
Strooper, B. D. (2000) · Nature · doi:10.1038/35015193 · Cited by 57
Presenilins and the intramembrane proteolysis of proteins: facts and fiction
Strooper, B. D., & Annaert, W. G. (2001) · Nature Cell Biology · doi:10.1038/ncb1001-e221 · Cited by 57
“Studies in fibroblasts derived from patients with familiar Alzheimer's disease (FAD) have shown that all clinical mutations of PS increase the relative proportion of secreted peptides ending at residue 42 (Aβ42) compared with those ending at residue 40 (Aβ40”
BackgroundAmyloid precursor protein, copper and Alzheimer's disease
Multhaup, G. (1997) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(97)86907-7 · Cited by 57
The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently
Shoji, M., Kanai, M., Matsubara, E., Tomidokoro, Y., Shizuka, M., Ikeda, Y., Ikeda, M., Harigaya, Y., Okamoto, K., & Hirai, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00229-3 · Cited by 50
Early- and Late-Onset Alzheimer’s Disease: Two Sides of the Same Coin?
Valdez-Gaxiola, C. A., Rosales-Leycegui, F., Gaxiola-Rubio, A., Moreno-Ortíz, J. M., & Figuera, L. E. (2024) · Diseases · doi:10.3390/diseases12060110 · Cited by 65
“Importantly, P3 is a soluble peptide that lacks the propensity to aggregate, unlike A β [54].”
BackgroundTriggering ferroptosis in neurodegenerative diseases
Nguyen, T. P. M., Alves, F. M., Lane, D. J. R., Bush, A. I., & Ayton, S. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.06.008 · Cited by 64
Hargus, G., Ehrlich, M., Hallmann, A.-L., & Kuhlmann, T. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1222-6 · Cited by 60
“Mutations in the presenilin 1 gene (PS1) and in the presenilin 2 gene (PS2) are common causes of fAD [48, 157] and have been described to enhance the production of Aβ protein, especially of Aβ42 [153].”
BackgroundPathogenic mechanisms in Alzheimer's disease
Pastorino, L., & Lu, K. P. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.078 · Cited by 60
Developing Preventive Therapies for Chronic Diseases: Lessons Learned from Alzheimer's Disease
Selkoe, D. J. (2008) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00370.x · Cited by 50
Self-citationAlberghina, L., & Colangelo, A. M. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-s1-s2 · Cited by 55
“Although Aβ 42 is constitutively produced in the brain, mutations in the APP or PS1/2 genes (which alter the cleavage specificity of γ-secretase) lead to increased production and accumulation of Aβ 42, that is neurotoxic even before its aggregation in Aβ fibrils [111].”
BackgroundLi, Q., Cao, C., Chackerian, B., Schiller, J., Gordon, M., Ugen, K. E., & Morgan, D. (2004) · BMC Neuroscience · doi:10.1186/1471-2202-5-21 · Cited by 50
Alzheimer's disease: molecular concepts and therapeutic targets
Fassbender, K. C., Masters, C. L., & Beyreuther, K. T. (2001) · Die Naturwissenschaften · doi:10.1007/s001140100237 · Cited by 61
Prevention and Reduction of AD‐type Pathology in PDAPP Mice Immunized with Aβ1–42
GAMES, D., BARD, F., GRAJEDA, H., GUIDO, T., KHAN, K., SORIANO, F., VASQUEZ, N., WEHNER, N., JOHNSON‐WOOD, K., YEDNOCK, T., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06936.x · Cited by 50
Presenilin Affects Arm/β-Catenin Localization and Function in Drosophila
Noll, E., Medina, M., Hartley, D. M., Zhou, J., Perrimon, N., & Kosik, K. S. (2000) · Developmental Biology · doi:10.1006/dbio.2000.9925 · Cited by 59
Layer‐specific alterations to CA1 dendritic spines in a mouse model of Alzheimer's disease
Merino‐Serrais, P., Knafo, S., Alonso‐Nanclares, L., Fernaud‐Espinosa, I., & DeFelipe, J. (2011) · Hippocampus · doi:10.1002/hipo.20861 · Cited by 50
“We used a transgenic mouse line (12 to 14-month-old male mice) expressing a Mo/Hu APP695swe construct in conjunction with the exon 9 deleted variant of human presenilin 1 (PS1-dE9: (Scheuner et al., 1996).”
MethodBelkacemi, A., & Ramassamy, C. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.11.020 · Cited by 54
Ooi, L., Sidhu, K., Poljak, A., Sutherland, G., O’Connor, M. D., Sachdev, P., & Münch, G. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-012-0839-2 · Cited by 48
“In the amyloidogenic pathway, APP is first cleaved by b-secretase (BACE1) to generate a slightly shorter N-terminal ectodomain, APPs-b (Borchelt et al. 1996; Scheuner et al. 1996; Tomita et al. 1997).”
BackgroundMartín‐Belmonte, A., Aguado, C., Alfaro‐Ruiz, R., Moreno‐Martínez, A. E., de la Ossa, L., Hernández, J. M., Buisson, A., Früh, S., Bettler, B., Shigemoto, R., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12802 · Cited by 53
Unraveling the complexity of γ-secretase
Wolfe, M. S. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.01.005 · Cited by 55
Rasagiline: an anti-Parkinson drug with neuroprotective activity
Youdim, M. B. (2003) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.3.6.737 · Cited by 48
Identification of New Presenilin Gene Mutations in Early-Onset Familial Alzheimer Disease
Tedde, A., Nacmias, B., Ciantelli, M., Forleo, P., Cellini, E., Bagnoli, S., Piccini, C., Caffarra, P., Ghidoni, E., Paganini, M., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.11.1541 · Cited by 49
Presenilins as therapeutic targets for the treatment of Alzheimer's disease
Golde, T. E., & Younkin, S. G. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02064-0 · Cited by 58
Self-citationClosing in on the Amyloid Cascade
Doms, R. W., & Huse, J. T. (2000) · Molecular Neurobiology · doi:10.1385/mn:22:1-3:081 · Cited by 67
“These same presenilin variants also increase the levels of Aβ42 detectable in human plasma (127).”
Background(1997) · Biological Chemistry · doi:10.1515/bchm.1997.378.9.937 · Cited by 49
Normal brain development in PS1 hypomorphic mice with markedly reduced γ-secretase cleavage of βAPP
Rozmahel, R. F., Huang, J., Chen, F., Liang, Y., Nguyen, V., Ikeda, M., Lévesque, G., Yu, G., Nishimura, M., Mathews, P. M., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00267-6 · Cited by 51
Alpha-B-Crystallin in Neuropathology
van Rijk, A. F., & BLOEMENDAL, H. (2000) · Ophthalmologica · doi:10.1159/000027468 · Cited by 50
Czech, C., Lesort, M. J., Tremp, G. L., Terro, F., Blanchard, V., Schombert, B., Carpentier, N., Dreisler, S., Bonici, B., Takashima, A., et al. (1998) · Neuroscience · doi:10.1016/s0306-4522(98)00162-6 · Cited by 51
Cho, Y. Y., Kwon, O.-H., Park, M. K., Kim, T.-W., & Chung, S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0210535 · Cited by 48
Reversible Pathologic and Cognitive Phenotypes in an Inducible Model of Alzheimer-Amyloidosis
Melnikova, T., Fromholt, S., Kim, H., Lee, D., Xu, G., Price, A., Moore, B. D., Golde, T. E., Felsenstein, K. M., Savonenko, A., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4251-12.2013 · Cited by 49
“…of proteolytic events (for review, see Lichtenthaler et al., 2011), generally lead to enhanced levels of A 42 peptides (Citron et al., 1992, 1997; Suzuki et al., 1994; Scheuner et al., 1996; Kwok et al., 2000; De Jonghe et al., 2001; Bentahir et al., 2006; Di et al., 2009; Zhou et al., 2011).”
BackgroundGenetic studies in Alzheimer's disease
Tang, Y.-P., & Gershon, E. S. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/yptang · Cited by 48
“Instead, these missense mutants significantly and specifically enhance γ-secretase cleavage to generate amyloidogenic Aβ42 peptides.(69,89,90,126,127) All these findings point to a central role for PS1 and PS2 in both APP processing and AD pathogenesis.”
BackgroundInactivation of γ‐secretases leads to accumulation of substrates and non‐Alzheimer neurodegeneration
Acx, H., Serneels, L., Radaelli, E., Muyldermans, S., Vincke, C., Pepermans, E., Müller, U., Chávez‐Gutiérrez, L., & De Strooper, B. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707561 · Cited by 49
“…are mainly qualitative, shifting the spectrum of A b peptides toward longer versions that are apparently able to seed disease (Borchelt et al , 1996; Duff et al , 1996; Scheuner et al , 1996; Bentahir et al , 2006; Cha´vez-Gutie´rrez et al , 2012; Szaruga et al , 2015; Veugelen et al , 2016).”
Tanemura, K., Chui, D.-H., Fukuda, T., Murayama, M., Park, J.-M., Akagi, T., Tatebayashi, Y., Miyasaka, T., Kimura, T., Hashikawa, T., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509145200 · Cited by 49
Familial conformational diseases and dementias
Crowther, D. C. (2002) · Human Mutation · doi:10.1002/humu.10100 · Cited by 52
“Various pathogenetic mutations in presenilin-1, and its homologue presenilin-2, result in an approximate doubling of Ab1–42 levels in patients’ plasma and in the medium of cultured skin fibroblasts [Scheuner et al., 1996].”
BackgroundGhersi, E., Noviello, C., & D'Adamio, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405329200 · Cited by 46
Mehta, P. D., Mehta, S. P., Fedor, B. L., Patrick, B. A., Emmerling, M. R., & Dalton, A. J. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00275-1 · Cited by 53
George, A. R., & Howlett, D. R. (1999) · Biopolymers · doi:10.1002/(sici)1097-0282(199912)50:7<733::aid-bip6>3.0.co;2-7 · Cited by 55
The genetics of Alzheimer's disease
Rubinsztein, D. C. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00014-2 · Cited by 55
Chasing genes in Alzheimer?s and Parkinson?s disease
Bertoli‐Avella, A. M., Oostra, B. A., & Heutink, P. (2004) · Human Genetics · doi:10.1007/s00439-004-1097-7 · Cited by 54
Sambamurti, K., Sevlever, D., Koothan, T., Refolo, L. M., Pinnix, I., Gandhi, S., Onstead, L., Younkin, L., Prada, C. M., Yager, D., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.26810 · Cited by 48
Self-citationDual Roles of Proteasome in the Metabolism of Presenilin 1
Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Takahashi, H., Murayama, O., Murayama, M., Sato, K., Omori, A., Tsubuki, S., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720255.x · Cited by 49
“…the pathological characteristics of mutations of PS1 and PS2 (Martins et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Lemere et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Tomita et al., 1997; Xia et al., 1997), the precise pathological and physiological roles of presenilins…”
BackgroundTate, B. A., & Mathews, P. M. (2006) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2006.10.re2 · Cited by 48
Clinical, biological, and imaging features of monogenic Alzheimer’s disease
Pilotto, A., Padovani, A., & Borroni, B. (2013) · BioMed Research International · doi:10.1155/2013/689591 · Cited by 47
Metabolism of amyloid β peptide and pathogenesis of Alzheimer’s disease
Saido, T. C. (2013) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.89.321 · Cited by 60
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.